Hypertrophic Cardiomopathy
Moira Kessler
Northwestern McGaw/Feinberg School of Medicine, Chicago, IL USA
Search for more papers by this authorSara Saberi
Division of Cardiovascular Medicine, University of Michigan, Ann Arbor, MI USA
Search for more papers by this authorSharlene Day
Division of Cardiovascular Medicine, University of Michigan, Ann Arbor, MI USA
Search for more papers by this authorTamara Gay
Department of Psychiatry, University of Michigan, Ann Arbor, MI, USA
Search for more papers by this authorLinda Baty
Division of Cardiovascular Medicine, University of Michigan, Ann Arbor, MI USA
Search for more papers by this authorC. Edward Deneke
Department of Psychiatry, University of Michigan, Ann Arbor, MI, USA
Search for more papers by this authorMoira Kessler
Northwestern McGaw/Feinberg School of Medicine, Chicago, IL USA
Search for more papers by this authorSara Saberi
Division of Cardiovascular Medicine, University of Michigan, Ann Arbor, MI USA
Search for more papers by this authorSharlene Day
Division of Cardiovascular Medicine, University of Michigan, Ann Arbor, MI USA
Search for more papers by this authorTamara Gay
Department of Psychiatry, University of Michigan, Ann Arbor, MI, USA
Search for more papers by this authorLinda Baty
Division of Cardiovascular Medicine, University of Michigan, Ann Arbor, MI USA
Search for more papers by this authorC. Edward Deneke
Department of Psychiatry, University of Michigan, Ann Arbor, MI, USA
Search for more papers by this authorMichelle Riba
Department of Psychiatry, University of Michigan, Ann Arbor, MI, USA
Search for more papers by this authorLawson Wulsin
Department of Psychiatry&Behavioral Neuroscience, University of Cincinnati, Cincinnati, OH, USA
Search for more papers by this authorMelvyn Rubenfire
Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA
Search for more papers by this authorSummary
Hypertrophic cardiomyopathy (HCM) is the most common genetic cardiovascular disease, affecting 0.2% of the general US population. While individuals with HCM overall have less physical disability than individuals suffering from other severe cardiac illnesses, they often suffer from more psychiatric disability. Much has been written about the medical management of symptoms and complications of HCM, but there has been limited investigation of the psychologic and social issues inherent to HCM. Overall, studies have reported that patients with HCM have more psychologic distress, increased anxiety and depression, and an impaired quality of life compared to the general population. Specifically, studies have shown that mood disorders in HCM patients were significantly associated with chest pain, older age, higher perceived risk of death, poorer social adjustment, and problems with sexual relations. Those at risk for anxiety disorders included individuals who were divorced or widowed, more likely to suffer chest pain, more likely to perceive themselves to be at higher risk of death, and to have more recent diagnoses. There is a need for further research in many different psychosocial issues of HCM such as determining whether there is an association between psychologic co-morbidities and cardiovascular prognosis in patients; the prevalence and risk factors for PTSD; and which psychologic interventions best alleviate patient and family distress.
References
- Maron BJ, Gardin JM, Flack JM, Gidding SS, Kurosaki TT, Bild DE. (1995) Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults. Circulation. 92(4): 785–9.
- Maron BJ, McKenna WJ, Danielson GK, Kappenberger LJ, Kuhn HJ, Seidman CE, et al. (2003) American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. J Am Coll Cardiol. 42 (9): 1687–713.
- Maron BJ. (2002) Hypertrophic cardiomyopathy: a systematic review. JAMA. 287(10): 1308–20.
- Maron MS, Olivotto I, Zenovich AG, Link MS, Pandian NG, Kuvin JT, (2006) Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction. Circulation. 114(21): 2232–9.
- Cox S, O'Donoghue AC, McKenna WJ, Steptoe A. (1997) Health related quality of life and psychological wellbeing in patients with hypertrophic cardiomyopathy. Heart. 78(2): 182–7.
- Niimura H, Bachinski LL, Sangwatanaroj S, Watkins H, Chudley AE, McKenna W, et al. (1998) Mutations in the gene for cardiac myosin-binding protein C and late-onset familial hypertrophic cardiomyopathy. N Engl J Med. 338(18): 1248–57.
- Maron BJ, Niimura H, Casey SA, Soper MK, Wright GB, Seidman JG, et al. (2001) Development of left ventricular hypertrophy in adults in hypertrophic cardiomyopathy caused by cardiac myosin-binding protein C gene mutations. J Am Coll Cardiol. 38(2): 315–21.
- Rosenzweig A, Watkins H, Hwang DS, Miri M, McKenna W, Traill TA, et al. (1991) Preclinical diagnosis of familial hypertrophic cardiomyopathy by genetic analysis of blood lymphocytes. N Engl J Med. 325(25): 1753–60.
- Spirito P, Seidman CE, McKenna WJ, Maron BJ. (1997) The management of hypertrophic cardiomyopathy. N Engl J Med. 336(11): 775–85.
- Nishimura RA, Holmes DR, Jr., (2004) Clinical practice. Hypertrophic obstructive cardiomyopathy. N Engl J Med. 350(13): 1320–7.
- Rochitte CE, Tassi EM, Shiozaki AA. (2006) The emerging role of MRI in the diagnosis and management of cardiomyopathies. Curr Cardiol Rep. 8(1): 44–52.
- Cohen LS, Braunwald E. (1967) Amelioration of angina pectoris in idiopathic hypertrophic subaortic stenosis with beta-adrenergic blockade. Circulation. 35(5): 847–51.
- Koch-Weser J, Frishman WH. (1981) ???beta-adrenoceptor antagonists: new drugs and new indications. N Engl J Med. 305(9): 500–6.
- Morrow AG. (1978) Hypertrophic subaortic stenosis. Operative methods utilized to relieve left ventricular outflow obstruction. J Thorac Cardiovasc Surg. 76(4): 423–30.
- Schulte HD, Borisov K, Gams E, Gramsch-Zabel H, Losse B, Schwartzkopff B. (1999) Management of symptomatic hypertrophic obstructive cardiomyopathy–long-term results after surgical therapy. Thorac Cardiovasc Surg. 47(4): 213–18.
- Seggewiss H, Gleichmann U, Faber L, Fassbender D, Schmidt HK, Strick S. (1998) Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: acute results and 3-month follow-up in 25 patients. J Am Coll Cardiol. 31(2): 252–8.
- Sigwart U. (1995) Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy. Lancet. 346(8969): 211–14.
- Elliott PM, Poloniecki J, Dickie S, Sharma S, Monserrat L, Varnava A, (2000) Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. J Am Coll Cardiol. 36(7): 2212–18.
- McKenna WJ, Oakley CM, Krikler DM, Goodwin JF. (1985) Improved survival with amiodarone in patients with hypertrophic cardiomyopathy and ventricular tachycardia. Br Heart J. 53(4): 412–16.
- Begley DA, Mohiddin SA, Tripodi D, Winkler JB, Fananapazir L. (2003) Efficacy of implantable cardioverter defibrillator therapy for primary and secondary prevention of sudden cardiac death in hypertrophic cardiomyopathy. Pacing Clin Electrophysiol. 26(9): 1887–96.
- Maron BJ, Shen WK, Link MS, Epstein AE, Almquist AK, Daubert JP, (2000) Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. N Engl J Med. 342(6): 365–73.
10.1056/NEJM200002103420601 Google Scholar
- Maron BJ, Spirito P, Shen WK, Haas TS, Formisano F, Link MS, et al. (2007) Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy. JAMA. 298(4): 405–12.
- Elliott PM, Gimeno Blanes JR, Mahon NG, Poloniecki JD, McKenna WJ. (2001) Relation between severity of left-ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy. Lancet. 357(9254): 420–4.
- Adabag AS, Casey SA, Kuskowski MA, Zenovich AG, Maron BJ. (2005) Spectrum and prognostic significance of arrhythmias on ambulatory Holter electrocardiogram in hyper-trophic cardiomyopathy. J Am Coll Cardiol. 45 (5): 697–704.
- Monserrat L, Elliott PM, Gimeno JR, Sharma S, Penas-Lado M, McKenna WJ. (2003) Non-sustained ventricular tachycardia in hypertrophic cardiomyopathy: an independent marker of sudden death risk in young patients. J Am Coll Cardiol. 42(5): 873–9.
- Olivotto I, Maron BJ, Montereggi A, Mazzuoli F, Dolara A, Cecchi F. (1999) Prognostic value of systemic blood pressure response during exercise in a community-based patient population with hypertrophic cardiomyopathy. J Am Coll Cardiol. 33(7): 2044–51.
- Spirito P, Bellone P, Harris KM, Bernabo P, Bruzzi P, Maron BJ. (2000) Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. N Engl J Med. 342(24): 1778–85.
- Maron BJ, Shirani J, Poliac LC, Mathenge R, Roberts WC, Mueller FO. (1996) Sudden death in young competitive athletes. Clinical, demographic, and pathological profiles. JAMA. 276(3): 199–204.
- Maron BJ, Doerer JJ, Haas TS, Tierney DM, Mueller FO. (2009) Sudden deaths in young competitive athletes: analysis of 1866 deaths in the United States, 1980–2006. Circulation. 119(8): 1085–92.
- Rowland T. (2007) Sudden cardiac death in athletes: rethinking “hypertropic cardiomyopathy”. Pediatr Exerc Sci. 19(4): 373–83.
- Ingles J, Lind JM, Phongsavan P, Semsarian C. (2008) Psychosocial impact of specialized cardiac genetic clinics for hypertrophic cardiomyopathy. Genet Med. 10(2): 117–20.
- Morgan JF, O'Donoghue AC, McKenna WJ, Schmidt MM. (2008) Psychiatric disorders in hypertrophic cardiomyopathy. Gen Hosp Psychiatry. 30(1): 49–54.
- Rosenfeld JE. (2006) Emotional and psychiatric issues in hypertrophic cardiomyopathy and other cardiac patients. Anadolu Kardiyol Derg. 6 Suppl 2: 5–8.
- Pablo Kaski J, Tome Esteban MT, Lowe M, Sporton S, Rees P, Deanfield JE, et al. (2007) Outcomes after implantable cardioverter-defibrillator treatment in children with hypertrophic cardiomyopathy. Heart. 93(3): 372–4.
- Duru F, Buchi S, Klaghofer R, Mattmann H, Sensky T, Buddeberg C, et al. How different from pacemaker patients are recipients of implantable cardioverter-defibrillators with respect to psychosocial adaptation, affective disorders, and quality of life? Heart. 85(4): 375–9.
- Schron EB, Exner DV, Yao Q, Jenkins LS, Steinberg JS, Cook JR, et al. (2002) Quality of life in the antiarrhythmics versus implantable defibrillators trial: impact of therapy and influence of adverse symptoms and defibrillator shocks. Circulation. 105(5): 589–94.
- Heller SS, Ormont MA, Lidagoster L, Sciacca RR, Steinberg S. (1998) Psychosocial outcome after ICD implantation: a current perspective. Pacing Clin Electrophysiol. 21(6): 1207–15.
- Burns JL, Sears SF, Sotile R, Schwartzman DS, Hoyt RH, Alvarez LG, et al. (2004) Do patients accept implantable atrial defibrillation therapy? Results from the Patient Atrial Shock Survey of Acceptance and Tolerance (PASSAT) Study. J Cardiovasc Electrophysiol. 15(3): 286–91.
- Pedersen SS, Theuns DA, MuskensHeemskerk A, Erdman RA, Jordaens L. (2007) Type-D personality but not implantable cardioverter-defibrillator indication is associated with impaired health-related quality of life 3 months post-implantation. Europace. 9(8): 675–80.
- Sears SF, Lewis TS, Kuhl EA, Conti JB. (2005) Predictors of quality of life in patients with implantable cardioverter defibrillators. Psychosomatics. 46(5): 451–7.
- Sears SF, Serber ER, Lewis TS, Walker RL, Conners N, Lee JT, et al. (2004) Do positive health expectations and optimism relate to quality-of-life outcomes for the patient with an implantable cardioverter defibrillator? J Cardiopulm Rehabil. 24(5): 324–331.
- DeMaso DR, Lauretti A, Spieth L, van der Feen JR, Jay KS, Gauvreau K, et al. Psychosocial factors and quality of life in children and adolescents with implantable cardioverter-defibrillators. Am JCardiol. 93(5): 582–7.
- Sola CL, Bostwick JM. (2005) Implantable cardioverter-defibrillators, induced anxiety, and quality of life. Mayo Clin Proc. 80(2): 232–7.
- Hamang A, Eide GE, Nordin K, Rokne B, Bjorvatn C, Oyen N. (date?) Health status in patients at risk of inherited arrhythmias and sudden unexpected death compared to the general population. BMC Med Genet. 11: 27.
- Christiaans I, van Langen IM, Birnie E, Bonsel GJ, Wilde AA, Smets EM. (2009) Quality of life and psychological distress in hypertrophic cardiomyopathy mutation carriers: a cross-sectional cohort study. Am J Med Genet A. 149A(4): 602–12.
- Hendriks KS, Hendriks MM, Birnie E, Grosfeld FJ, Wilde AA, van den Bout J, et al. (2008) Familial disease with a risk of sudden death: a longitudinal study of the psychological consequences of predictive testing for long QT syndrome. Heart Rhythm. 5(5): 719–24.
- Heshka JT, Palleschi C, Howley H, Wilson B, Wells PS. (2008) A systematic review of perceived risks, psychological and behavioral impacts of genetic testing. Genet Med. 10(1): 19–32.
- van Maarle MC, Stouthard ME, Bonsel GJ. (2003) Quality of life in a family based genetic cascade screening programme for familial hypercholesterolaemia: a longitudinal study among participants. J Med Genet. 40(1): e3.
- Barnes C, Marteau T, Evers-Kiebooms G. (1997) Report of the Fifth European Meeting on Psychosocial Aspects of Genetics. J Med Genet. 34(4): 346–8.
- Lerman C, Croyle RT, Tercyak KP, Hamann H. (2002) Genetic testing: psychological aspects and implications. J Consult Clin Psychol. 70(3): 784–97.